UK-based digital health company Congenica has announced a partnership with biotechnology company Avesthagen in a bid to grow its presence in India.
Congenica enables precision medicine through its diagnostic platform for genomic data while Avesthagen creates personalised healthcare through the convergence of food, pharma and population genetics.
Congenica’s automated, AI-powered platform will provide genomic analysis and reporting for Avgen Diagnostics.
The platform offers whole genome and exome-based diagnostics for predictive and preventative healthcare across India.
The platfom will enable Avesthagen’s customers to quickly and accurately interpret sequencing data, potentially speeding up diagnosis, improving patient outcomes and reducing strain on the healthcare system.
Willem Haagmans, Vice-President Sales EMEA at Congenica, said:
“Developing partnerships with like-minded leaders in their field around the globe is a core part of our strategy going forwards, with the aim of helping more people around the globe access precision medicine.
“We are delighted to be working with Avesthagen, supporting their wider portfolio with our powerful and scalable platform that will enable healthcare providers across India to benefit from the rapid transformation of data into actionable insights and improve patient outcomes.”
Dr Villoo Morawala Patell, Chairperson and Managing Director of Avesthagen and The Avestagenome ProjectR, said:
“Congenica is the world’s leading software for the analysis, interpretation and reporting of genomic data and we are excited to enter this partnership with them.
“Their experience and success with national genome projects including Genomics England, and extensive work for the NHS, will help us to accelerate preventive and early diagnosis to deliver personalised medicine across India.
“Our new offering represents a paradigm shift in understanding disease and providing precise treatments and we’re looking forward to a successful future with Congenica as our partner.”
Last week, Congenica announced that it has expended its reach into the cancer field through a partnership with GenomOncology in the US.
